Evidence map›Paper›PMID 34799404›Full record

ArticleMolecular cancer research : MCR2022

Disruption of β-Catenin-Dependent Wnt Signaling in Colon Cancer Cells Remodels the Microenvironment to Promote Tumor Invasion.

George T Chen, Delia F Tifrea, Rabi Murad, Amber N Habowski, Yung Lyou, Madeleine R Duong, Linzi Hosohama, Ali Mortazavi, Robert A Edwards, Marian L Waterman

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

George T ChenDepartment of Microbiology and Molecular Genetics, University of California, Irvine, California.
Delia F TifreaDepartment of Pathology, University of California, Irvine, California.ORCID 0000-0002-7531-9337
Rabi MuradDepartment of Developmental and Cell Biology, University of California, Irvine, California.
Amber N HabowskiDepartment of Microbiology and Molecular Genetics, University of California, Irvine, California.ORCID 0000-0003-1107-3208
Yung LyouDepartment of Microbiology and Molecular Genetics, University of California, Irvine, California.
Madeleine R DuongDepartment of Microbiology and Molecular Genetics, University of California, Irvine, California.
Linzi HosohamaDepartment of Microbiology and Molecular Genetics, University of California, Irvine, California.
Ali MortazaviDepartment of Developmental and Cell Biology, University of California, Irvine, California.
Robert A EdwardsDepartment of Pathology, University of California, Irvine, California.ORCID 0000-0001-9145-382X
Marian L WatermanDepartment of Microbiology and Molecular Genetics, University of California, Irvine, California.ORCID 0000-0003-4823-4968
University of California, Irvine · US

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Christine Hui · 1994 to 2026
$57.9M
Shared Resource Core: Single Cell AnalysisU54CA217378 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI VAN ETTEN, RICHARD A. · 2018 to 2022
$9.7M
CARCINOGENESIST32CA009054 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI EDINGER, AIMEE L, FRUMAN, DAVID ALEXANDER · 1985 to 2025
$8.6M
LEF/TCF Expression in Colon CancerR01CA096878 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI WATERMAN, MARIAN L · 2003 to 2012
$2.7M
Wnt Signaling in Colon CancerR01CA108697 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI WATERMAN, MARIAN L · 2005 to 2015
$2.7M
PacBio RS Single Molecule, Real-Time (SMRT) DNA SequencerS10OD010794 · OD · UNIVERSITY OF CALIFORNIA-IRVINE · PI SANDMEYER, SUZANNE · 2012 to 2012
$600k
High Throughput DNA SequencerS10RR025496 · NCRR · UNIVERSITY OF CALIFORNIA-IRVINE · PI SANDMEYER, SUZANNE · 2009 to 2009
$500k
Therapeutic targeting of Wnt & Metabolism in Colon CancerR03CA223929 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI WATERMAN, MARIAN L · 2019 to 2020
$155k
Regulation of Wnt Signaling in Invasive Colon CancerF31CA200298 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI CHEN, GEORGE TSUN-TE · 2015 to 2017
$112k
NCI NIH HHS F31 CA200298NCI NIH HHS P30 CA062203NCI NIH HHS R01 CA096878NCI NIH HHS R01 CA108697NCI NIH HHS R03 CA223929NCI NIH HHS T32 CA009054NCI NIH HHS U54 CA217378NCRR NIH HHS S10 RR025496NIH HHS S10 OD010794
6 · The paper itself

Abstract

The recent classification of colon cancer into molecular subtypes revealed that patients with the poorest prognosis harbor tumors with the lowest levels of Wnt signaling. This is contrary to the general understanding that overactive Wnt signaling promotes tumor progression from early initiation stages through to the later stages including invasion and metastasis. Here, we directly test this assumption by reducing the activity of ß-catenin-dependent Wnt signaling in colon cancer cell lines at either an upstream or downstream step in the pathway. We determine that Wnt-reduced cancer cells exhibit a more aggressive disease phenotype, including increased mobility in vitro and disruptive invasion into mucosa and smooth muscle in an orthotopic mouse model. RNA sequencing reveals that interference with Wnt signaling leads to an upregulation of gene programs that favor cell migration and invasion and a downregulation of inflammation signatures in the tumor microenvironment. We identify a set of upregulated genes common among the Wnt perturbations that are predictive of poor patient outcomes in early-invasive colon cancer. Our findings suggest that while targeting Wnt signaling may reduce tumor burden, an inadvertent side effect is the emergence of invasive cancer. IMPLICATIONS: Decreased Wnt signaling in colon tumors leads to a more aggressive disease phenotype due to an upregulation of gene programs favoring cell migration in the tumor and downregulation of inflammation programs in the tumor microenvironment; these impacts must be carefully considered in developing Wnt-targeting therapies.

Indexed as

beta CateninColonic NeoplasmsAnimalsCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansInflammationMiceTumor MicroenvironmentWnt Signaling Pathwaybeta Catenin

Identifiers

PMID34799404
PMCPMC8898281
OpenAlexW3212222179

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.